Bessemer Group Inc. Boosts Position in Medtronic PLC $MDT

Bessemer Group Inc. raised its stake in Medtronic PLC (NYSE:MDT) by 86.2% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 2,538,029 shares of the medical technology company’s stock after buying an additional 1,174,765 shares during the period. Bessemer Group Inc.’s holdings in Medtronic were worth $241,723,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. Riverbend Wealth Management LLC grew its stake in Medtronic by 3.2% in the third quarter. Riverbend Wealth Management LLC now owns 3,487 shares of the medical technology company’s stock worth $332,000 after purchasing an additional 107 shares in the last quarter. Wynn Capital LLC raised its position in Medtronic by 2.4% during the 3rd quarter. Wynn Capital LLC now owns 4,639 shares of the medical technology company’s stock valued at $442,000 after purchasing an additional 110 shares in the last quarter. Meridian Investment Counsel Inc. lifted its holdings in shares of Medtronic by 0.4% in the 3rd quarter. Meridian Investment Counsel Inc. now owns 28,268 shares of the medical technology company’s stock worth $2,692,000 after buying an additional 110 shares during the period. Saxony Capital Management LLC grew its position in shares of Medtronic by 3.8% during the 3rd quarter. Saxony Capital Management LLC now owns 3,046 shares of the medical technology company’s stock worth $290,000 after buying an additional 112 shares in the last quarter. Finally, Cape Investment Advisory Inc. increased its stake in shares of Medtronic by 3.2% during the second quarter. Cape Investment Advisory Inc. now owns 3,605 shares of the medical technology company’s stock valued at $314,000 after buying an additional 113 shares during the period. 82.06% of the stock is currently owned by institutional investors.

Medtronic Price Performance

Shares of NYSE MDT opened at $101.81 on Thursday. The firm has a market cap of $130.52 billion, a P/E ratio of 27.44, a P/E/G ratio of 2.72 and a beta of 0.71. Medtronic PLC has a 52 week low of $79.55 and a 52 week high of $106.33. The business’s 50 day moving average price is $99.48 and its 200 day moving average price is $95.96. The company has a quick ratio of 1.80, a current ratio of 2.42 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last announced its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The firm had revenue of $8.96 billion for the quarter, compared to the consensus estimate of $8.86 billion. During the same period in the prior year, the firm posted $1.26 earnings per share. The firm’s quarterly revenue was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, sell-side analysts expect that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, January 16th. Shareholders of record on Friday, December 26th were paid a dividend of $0.71 per share. The ex-dividend date of this dividend was Friday, December 26th. This represents a $2.84 annualized dividend and a yield of 2.8%. Medtronic’s dividend payout ratio (DPR) is 76.55%.

Analyst Ratings Changes

A number of analysts recently weighed in on MDT shares. The Goldman Sachs Group set a $111.00 price objective on shares of Medtronic and gave the stock a “neutral” rating in a research note on Wednesday, November 19th. Citigroup began coverage on shares of Medtronic in a report on Tuesday. They issued a “buy” rating and a $117.00 price target for the company. UBS Group reaffirmed a “neutral” rating and issued a $104.00 price target on shares of Medtronic in a research report on Wednesday. Daiwa Capital Markets lifted their price objective on shares of Medtronic from $104.00 to $117.00 and gave the company a “buy” rating in a report on Tuesday, November 25th. Finally, Truist Financial lowered their target price on Medtronic from $110.00 to $107.00 and set a “hold” rating for the company in a report on Thursday, December 18th. Fifteen research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. According to MarketBeat.com, Medtronic currently has a consensus rating of “Moderate Buy” and an average price target of $110.67.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic will exercise its option to acquire CathWorks for up to $585 million, adding AI-enabled coronary imaging/diagnostics to its interventional cardiology and cath-lab portfolio — a clear strategic bolt-on that could expand addressable market and recurring software/diagnostic revenues. Medical device maker Medtronic to buy CathWorks in up to $585 million deal Medtronic advances its innovation strategy with intent to acquire CathWorks
• Positive Sentiment: New analyst coverage: Citigroup started coverage with a Buy rating and $117 price target (roughly mid-teens upside from current levels), which can support renewed investor demand and higher price targets among peers.
• Positive Sentiment: Recent quarterly results showed an earnings beat and management set FY26 EPS guidance in the $5.62–$5.66 range, signaling durable margins and cash flow that underpin dividend safety and buyback capacity.
• Positive Sentiment: Dividend/quality narrative remains supportive: coverage highlighting Medtronic as a reliable dividend healthcare pick reinforces interest from income-oriented investors. 2 Healthcare Dividend Stocks That are Just What the Doctor Ordered
• Neutral Sentiment: Company messaging and product launch activity emphasize expansion of heart and diabetes tools, but a recent article notes Medtronic’s valuation is approaching analyst targets — suggesting limited near-term upside unless acceleration in top-line or margin improvement shows up. Medtronic Expands Heart And Diabetes Tools As Valuation Nears Analyst Views
• Negative Sentiment: Leadership change: Nina Goodheart, President of Structural Heart, is retiring — a near-term governance/operational uncertainty for a key growth business that could weigh on sentiment until succession clarity is provided. Medtronic Structural Heart President Nina Goodheart to retire

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).